Your search returned 53 results. Subscribe to this search

|
1. Intermittent left bundle branch block and acute heart failure in trastuzumab-induced cardiotoxicity

by Masson, Ravi.

Published: 2020; ; ; Citation: BMJ Case Reports. 13(7), 2020 Jul 28.; .Institution: MedStar Washington Hospital Center.Department: Medicine/Internal Medicine.Publication: Journal Article.Article type: Journal Article.Full author list: Bakhshi H; Haddad TM; Masson R.UI/PMID: 32723779.Online Access: Click here to access online Digital Object Identifier: https://dx.doi.org/10.1136/bcr-2020-236009 (Click here)
2. The Role of Angiotensin-Converting Enzyme Inhibitors and beta-Blockers in Primary Prevention of Cardiac Dysfunction in Breast Cancer Patients. [Review]

by Barac, Ana.

Published: 2020; ; ; Citation: Journal of the American Heart Association. 9(2):e015327, 2020 01 21.; .Institution: MedStar Heart & Vascular Institute.Publication: Journal Article.Article type: Journal Article.Full author list: Barac A; Brown SA; Okwuosa TM; Volgman AS.UI/PMID: 31960742.Digital Object Identifier: https://dx.doi.org/10.1161/JAHA.119.015327https://dx.doi.org/10.1161/JAHA.119.015327 (Click here) | (Click here)
3. Trastuzumab-Induced Cardiomyopathy. [Review]

by Barac, Ana; Gates, Emily.

Published: 2019; Citation: Cardiology Clinics. 37(4):407-418, 2019 Nov..Institution: MedStar Heart & Vascular Institute.Publication: Journal Article.Article type: Journal Article; Review.Full author list: Barac A; Barish R; Gates E.UI/PMID: 31587782.Online Access: Click here to access online Digital Object Identifier: https://dx.doi.org/10.1016/j.ccl.2019.07.005 (Click here)
4. Physician Perspectives on Fertility Preservation Discussions with Premenopausal Breast Cancer Patients: Results from a Multihospital Health Care System

by Bozzuto, Laura M; Haslinger, Michelle; Thibodeau, Renee; Tsiapali, Ekaterini V; Tung, Shawndeep S.

Published: 2019; ; Citation: Annals of Surgical Oncology. 2019 Jul 24; .Institution: MedStar Washington Hospital Center.Department: Surgery/Plastic Surgery.Publication: Journal Article.Article type: Journal Article.Full author list: Bartholomew AJ; Bozzuto LM; Haslinger M; Masciello MC; Thibodeau R; Tsiapali EV; Tung SS.UI/PMID: 31342399.Online Access: Click here to access online Digital Object Identifier: https://dx.doi.org/10.1245/s10434-019-07563-w (Click here)
5. Neoadjuvant Chemotherapy and Nipple-Sparing Mastectomy: Timing and Postoperative Complications

by Dervishaj, Ornela A; Tung, Shawndeep S.

Published: 2019; ; Citation: Annals of Surgical Oncology. 26(9):2768-2772, 2019 Sep.; .Institution: MedStar Washington Hospital Center.Department: Surgery/Plastic Surgery.Publication: Journal Article.Article type: Journal Article.Full author list: Bartholomew AJ; Caragacianu DL; Dervishaj OA; Kerivan LT; Sosin M; Tousimis EA; Tung SS; Willey SC.UI/PMID: 31123933.Digital Object Identifier: https://dx.doi.org/10.1245/s10434-019-07418-4 (Click here)
6. Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study

by Asch, Federico M; Barac, Ana; Cunningham, A; Gallagher, Christopher; Hofmeyer, Mark; Srichai, M B; Swain, Sandra M.

Published: 2019; Citation: Breast Cancer Research & Treatment. 175(3):595-603, 2019 Jun..Institution: MedStar Health ; MedStar Health Research Institute; MedStar Heart & Vascular Institute; Washington Cancer Institute.Department: Associate Dean for Research Development.Publication: Journal Article.Article type: Journal Article.Full author list: Asch FM; Barac A; Cunningham A; Dang C; Gallagher C; Geng X; Herbolsheimer P; Hofmeyer M; Isaacs C; Lynce F; Nunes R; Pohlmann PR; Shajahan-Haq A; Smith KL; Srichai MB; Swain SM; Tan MT; Timothee P; Warren R; Yu AF.UI/PMID: 30852761.Online Access: Click here to access online Digital Object Identifier: https://dx.doi.org/10.1007/s10549-019-05191-2 (Click here)
7. Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors

by Barac, Ana.

Published: ; ; 2019Citation: Breast Cancer Research & Treatment. 174(3):785-794, 2019 Apr..Institution: MedStar Heart & Vascular Institute.Publication: Journal Article.Article type: Journal Article.Full author list: Xu X; Chlebowski RT; Shi J; Barac A; Haque R.UI/PMID: 30659431.Digital Object Identifier: https://dx.doi.org/10.1007/s10549-018-05086-8 (Click here)
8. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial

by McCarron, Edward C.

Published: ; 2019; ; Citation: ; Lancet Oncology. 20(1):88-99, 2019 01..Institution: MedStar Franklin Square Medical Center.Publication: Journal Article.Article type: Journal Article.Full author list: Bandos H; Brufsky AM; Chia SK; Dakhil SR; Fehrenbacher L; Geyer CE Jr; Graham ML; Jeong JH; Lembersky BC; Mamounas EP; McCarron EC; Paik S; Rastogi P; Seay TE; Soori GS; Swain SM; Wade JL 3rd; Walshe JM; Wickerham DL; Wolmark N.UI/PMID: 30509771.Online Access: Click here to access online Digital Object Identifier: https://dx.doi.org/10.1016/S1470-2045(18)30621-1 (Click here)
9. Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase I clinical trials

by Lynce, Filipa; Blackburn, Matthew J.

Published: ; 2018Citation: Breast Cancer Research & Treatment. 168(1):35-41, 2018 Feb..Institution: Washington Cancer Institute; MedStar Washington Hospital Center.Department: Hematology and Oncology.Publication: Journal Article.Article type: Journal Article.Full author list: Lynce F; Blackburn MJ; Cai L; Wang H; Rubinstein L; Harris P; Isaacs C; Pohlmann PR.UI/PMID: 29119354.Digital Object Identifier: https://dx.doi.org/10.1007/s10549-017-4563-3 (Click here)
10. The effect of genetic variants on the relationship between statins and breast cancer in postmenopausal women in the Women's Health Initiative observational study

by Howard, Barbara V.

Published: 2018Citation: ; Breast Cancer Research & Treatment. 167(3):741-749, 2018 02..Institution: MedStar Health Research Institute.Publication: Journal Article.Article type: Journal Article.Full author list: Bock CH; Jay AM; Dyson G; Beebe-Dimmer JL; Cote ML; Hou L; Howard BV; Desai P; Purrington K; Prentice R; Simon MS.UI/PMID: 29063981.Online Access: Click here to access online Digital Object Identifier: https://dx.doi.org/10.1007/s10549-017-4521-0 (Click here)
11. Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2

by Swain, Sandra M; Zapas, John L.

Published: 2017Citation: Journal of Clinical Oncology. 35(35):3942-3948, 2017 Dec 10.Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article.Full author list: Ganz PA; Romond EH; Cecchini RS; Rastogi P; Geyer CE Jr; Swain SM; Jeong JH; Fehrenbacher L; Gross HM; Brufsky AM; Flynn PJ; Wahl TA; Seay TE; Wade JL 3rd; Biggs DD; Atkins JN; Polikoff J; Zapas JL; Mamounas EP; Wolmark N.UI/PMID: 29072977.Online Access: Click here to access online Digital Object Identifier: https://dx.doi.org/10.1200/JCO.2017.74.1165 (Click here)
12. Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30

by Swain, Sandra M; McCarron, Edward C.

Published: 2018Citation: Journal of the National Cancer Institute. 110(2), 2018 Feb 01.Institution: Washington Cancer Institute; MedStar Franklin Square Medical Center.Publication: Journal Article.Article type: Journal Article.Full author list: Bandos H; Melnikow J; Rivera DR; Swain SM; Sturtz K; Fehrenbacher L; Wade JL 3rd; Brufsky AM; Julian TB; Margolese RG; McCarron EC; Ganz PA.UI/PMID: 28954297.Digital Object Identifier: https://dx.doi.org/10.1093/jnci/djx162 (Click here)
13. The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40

by Swain, Sandra M.

Published: 2016Citation: Annals of Surgical Oncology. 24(7):1853-1860, 2017 Jul.Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article.Full author list: Bear HD; Tang G; Rastogi P; Geyer CE Jr; Zoon CK; Kidwell KM; Robidoux A; Baez-Diaz L; Brufsky AM; Mehta RS; Fehrenbacher L; Young JA; Senecal FM; Gaur R; Margolese RG; Adams PT; Gross HM; Costantino JP; Paik S; Swain SM; Mamounas EP; Wolmark N.UI/PMID: 27864694.Online Access: Click here to access online Digital Object Identifier: https://dx.doi.org/10.1245/s10434-016-5662-9 (Click here)
14. Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial

by Swain, Sandra M.

Published: 2017Citation: JAMA Oncology. 3(3):335-341, 2017 Mar 01.Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial.Full author list: Gavin PG; Song N; Kim SR; Lipchik C; Johnson NL; Bandos H; Finnigan M; Rastogi P; Fehrenbacher L; Mamounas EP; Swain SM; Wickerham DL; Geyer CE Jr; Jeong JH; Costantino JP; Wolmark N; Paik S; Pogue-Geile KL.UI/PMID: 27812689.Digital Object Identifier: https://dx.doi.org/10.1001/jamaoncol.2016.4884 (Click here)
15. HALT-D: A Phase II Evaluation of Crofelemer for the Prevention and Prophylaxis of Diarrhea in Patients With Breast Cancer on Pertuzumab-Based Regimens

by Swain, Sandra M.

Published: 2017Citation: Clinical Breast Cancer. 17(1):76-78, 2017 Feb.Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article.Full author list: Gao JJ; Tan M; Pohlmann PR; Swain SM.UI/PMID: 27692565.Online Access: Click here to access online Digital Object Identifier: https://dx.doi.org/10.1016/j.clbc.2016.08.005 (Click here)
16. Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5

by Swain, Sandra M.

Published: 2017Citation: Clinical Breast Cancer. 17(1):48-54.e3, 2017 Feb.Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article.Full author list: Smith JW 2nd; Buyse ME; Rastogi P; Geyer CE Jr; Jacobs SA; Patocskai EJ; Robidoux A; Conlin AK; Ansari B; Keogh GP; Stella PJ; Gross HM; Lord RS; Polikoff JA; Mauquoi C; Mamounas EP; Swain SM; Wolmark N.UI/PMID: 27693116.Online Access: Click here to access online Digital Object Identifier: https://dx.doi.org/10.1016/j.clbc.2016.07.008 (Click here)
17. SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function

by Lynce, Filipa; Barac, Ana; Asch, Federico M; Swain, Sandra M.

Published: 2017Citation: Oncologist. 22(5):518-525, 2017 May.Institution: Washington Cancer Institute; MedStar Heart & Vascular Institute.Publication: Journal Article.Article type: Journal Article.Full author list: Lynce F; Barac A; Tan MT; Asch FM; Smith KL; Dang C; Isaacs C; Swain SM.UI/PMID: 28314836.Digital Object Identifier: https://dx.doi.org/10.1634/theoncologist.2016-0412 (Click here)
18. Pertuzumab for the treatment of breast cancer: a safety review. [Review]

by Swain, Sandra M.

Published: 2016Citation: Expert Opinion on Drug Safety. 15(6):853-63, 2016 Jun.Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article; Review.Full author list: Gao J; Swain SM.UI/PMID: 26982349.Digital Object Identifier: https://dx.doi.org/10.1517/14740338.2016.1167185 (Click here)
19. Cardiovascular Disease After Aromatase Inhibitor Use

by Barac, Ana.

Published: 2016Citation: JAMA Oncology. 2(12):1590-1597, 2016 Dec 01.Institution: MedStar Heart & Vascular Institute.Publication: Journal Article.Article type: Journal Article.Full author list: Haque R; Shi J; Schottinger JE; Chung J; Avila C; Amundsen B; Xu X; Barac A; Chlebowski RT.UI/PMID: 27100398.Digital Object Identifier: https://dx.doi.org/10.1001/jamaoncol.2016.0429 (Click here)
20. The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl

by Swain, Sandra M.

Published: 2016Citation: Breast Cancer Research & Treatment. 155(2):235-51, 2016 Jan..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article.Full author list: Dine JL; O'Sullivan CC; Voeller D; Greer YE; Chavez KJ; Conway CM; Sinclair S; Stone B; Amiri-Kordestani L; Merchant AS; Hewitt SM; Steinberg SM; Swain SM; Lipkowitz S.UI/PMID: 26759246.
21. Cardiac function in BRCA1/2 mutation carriers with history of breast cancer treated with anthracyclines

by Barac, Ana; Lynce, Filipa; Mete, Mihriye; Shara, Nawar M; Asch, Federico M; Wray, Lynette; Herbolsheimer, Pia M; Nunes, Raquel; Swain, Sandra M.

Published: 2016Citation: Breast Cancer Research & Treatment. 155(2):285-93, 2016 Jan..Institution: MedStar Washington Hospital Center; Washington Cancer Institute; MedStar Health Research Institute; MedStar Health Research Institute; MedStar Washington Hospital Center; MedStar Health Research Institute; Washington Cancer Instituteia; Washington Cancer Institute A; Washington Cancer Institute.Department: MedStar Heart Institute; MedStar Heart Institute.Publication: Journal Article.Article type: Journal Article.Full author list: Barac A; Lynce F; Smith KL; Mete M; Shara NM; Asch FM; Nardacci MP; Wray L; Herbolsheimer P; Nunes RA; Swain SM; Warren R; Peshkin BN; Isaacs C.UI/PMID: 26749359.
22. Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38

by Swain, Sandra M.

Published: 2016Citation: Cancer Epidemiology, Biomarkers & Prevention. 25(1):51-9, 2016 Jan..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article; Multicenter Study; Randomized Controlled Trial.Full author list: Cecchini RS; Swain SM; Costantino JP; Rastogi P; Jeong JH; Anderson SJ; Tang G; Geyer CE Jr; Lembersky BC; Romond EH; Paterson AH; Wolmark N.UI/PMID: 26545405.Digital Object Identifier: http://dx.doi.org/10.1158/1055-9965.EPI-15-0334-T (Click here)
23. Acquired von Willebrand disease and multiple myeloma: a case report of a breast cancer survivor

by Jin, Ning; Salahuddin, Farah F; Nesbitt, John A.

Edition: Blood Coagulation & Fibrinolysis. 25(8):890-3, 2014 Dec.Published: Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis ; 2014Institution: MedStar Union Memorial Hospital.Department: Medicine.Publication: Journal Article.Article type: Case Reports; Journal Article.UI/PMID: 24911454.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1097/MBC.0000000000000149 (Click here)
24. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial

by Swain, Sandra M.

Citation: Lancet Oncology. 16(9):1037-48, 2015 Sep..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't.Full author list: Bear HD; Tang G; Rastogi P; Geyer CE Jr; Liu Q; Robidoux A; Baez-Diaz L; Brufsky AM; Mehta RS; Fehrenbacher L; Young JA; Senecal FM; Gaur R; Margolese RG; Adams PT; Gross HM; Costantino JP; Paik S; Swain SM; Mamounas EP; Wolmark N.UI/PMID: 26272770.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1016/S1470-2045(15)00041-8 (Click here)
25. Reply to a. Avan et Al

by Swain, Sandra M.

Citation: Journal of Clinical Oncology. 33(15):1712, 2015 May 20..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Comment; Letter.Full author list: Baselga J; Clark E; Kiermaier A; Swain S.UI/PMID: 25870094.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1200/JCO.2015.60.8398 (Click here)
26. Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial

by Swain, Sandra M.

Citation: Journal of Clinical Oncology. 33(12):1340-7, 2015 Apr 20..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't.Full author list: Pogue-Geile KL; Song N; Jeong JH; Gavin PG; Kim SR; Blackmon NL; Finnigan M; Rastogi P; Fehrenbacher L; Mamounas EP; Swain SM; Wickerham DL; Geyer CE Jr; Costantino JP; Wolmark N; Paik S.UI/PMID: 25559813.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1200/JCO.2014.56.2439 (Click here)
27. Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study. []

by Swain, Sandra M.

Citation: Breast Cancer Research & Treatment. 149(1):163-9, 2015 Jan..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't.Full author list: Tan AR; Johannes H; Rastogi P; Jacobs SA; Robidoux A; Flynn PJ; Thirlwell MP; Fehrenbacher L; Stella PJ; Goel R; Julian TB; Provencher L; Bury MJ; Bhatt K; Geyer CE Jr; Swain SM; Mamounas EP; Wolmark N.UI/PMID: 25542269.Digital Object Identifier: http://dx.doi.org/10.1007/s10549-014-3221-2 (Click here)
28. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831

by Swain, Sandra M.

Citation: Journal of Clinical Oncology. 32(33):3744-52, 2014 Nov 20..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't.Full author list: Perez EA; Romond EH; Suman VJ; Jeong JH; Sledge G; Geyer CE Jr; Martino S; Rastogi P; Gralow J; Swain SM; Winer EP; Colon-Otero G; Davidson NE; Mamounas E; Zujewski JA; Wolmark N.UI/PMID: 25332249.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1200/JCO.2014.55.5730 (Click here)
29. Treatment of HER2-positive metastatic breast cancer

by Swain, Sandra M.

Citation: New England Journal of Medicine. 372(20):1964-5, 2015 May 14..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Comment; Letter.Full author list: Swain SM; Clark E; Baselga J.UI/PMID: 25970056.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1056/NEJMc1503446 (Click here)
30. Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA

by Swain, Sandra M.

Citation: Oncologist. 19(7):693-701, 2014 Jul..Institution: Washington Cancer Institute.Publication: Journal Article.Full author list: Swain SM; Im YH; Im SA; Chan V; Miles D; Knott A; Clark E; Ross G; Baselga J.UI/PMID: 24869931.Digital Object Identifier: http://dx.doi.org/10.1634/theoncologist.2014-0033 (Click here)
31. The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer

by Swain, Sandra M.

Citation: BMC Cancer. 14:307, 2014..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't.Full author list: Tripathy D; Rugo HS; Kaufman PA; Swain S; O'Shaughnessy J; Jahanzeb M; Mason G; Beattie M; Yoo B; Lai C; Masaquel A; Hurvitz S.UI/PMID: 24885258.Digital Object Identifier: http://dx.doi.org/10.1186/1471-2407-14-307 (Click here)
32. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer

by Swain, Sandra M.

Citation: New England Journal of Medicine. 372(8):724-34, 2015 Feb 19..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't.Full author list: Swain SM; Baselga J; Kim SB; Ro J; Semiglazov V; Campone M; Ciruelos E; Ferrero JM; Schneeweiss A; Heeson S; Clark E; Ross G; Benyunes MC; Cortes J; CLEOPATRA Study Group.UI/PMID: 25693012.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1056/NEJMoa1413513 (Click here)
33. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer

by Swain, Sandra M.

Citation: Journal of Clinical Oncology. 32(33):3753-61, 2014 Nov 20..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't.Full author list: Baselga J; Cortes J; Im SA; Clark E; Ross G; Kiermaier A; Swain SM.UI/PMID: 25332247.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1200/JCO.2013.54.5384 (Click here)
34. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA

by Swain, Sandra M.

Citation: Annals of Oncology. 25(6):1116-21, 2014 Jun..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't.Full author list: Swain SM; Baselga J; Miles D; Im YH; Quah C; Lee LF; Cortes J.UI/PMID: 24685829.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1093/annonc/mdu133 (Click here)
35. Pertuzumab for the treatment of breast cancer. [Review]

by Swain, Sandra M; Lynce, Filipa.

Citation: Cancer Investigation. 32(8):430-8, 2014 Oct..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article; Research Support, Non-U.S. Gov't; Review.Full author list: Lynce F; Swain SM.UI/PMID: 24921704.Digital Object Identifier: http://dx.doi.org/10.3109/07357907.2014.922570 (Click here)
36. Pertuzumab: increasing the options

by Nunes, Raquel; Swain, Sandra M.

Citation: Oncology (Williston Park). 28(3):199, 204, 210, 2014 Mar..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Comment; Journal Article; Research Support, Non-U.S. Gov't.Full author list: Nunes R; Swain SM.UI/PMID: 24855727.Online Access: Click here to access online
37. Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)

by Swain, Sandra M.

Citation: Breast Cancer Research & Treatment. 142(1):89-99, 2013 Nov..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't.Full author list: Miles D; Baselga J; Amadori D; Sunpaweravong P; Semiglazov V; Knott A; Clark E; Ross G; Swain SM.UI/PMID: 24129974.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1007/s10549-013-2710-z (Click here)
38. Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer

by Swain, Sandra M.

Citation: Annals of Oncology. 24(10):2630-5, 2013 Oct..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't.Full author list: Cortes J; Baselga J; Im YH; Im SA; Pivot X; Ross G; Clark E; Knott A; Swain SM.UI/PMID: 23868905.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1093/annonc/mdt274 (Click here)
39. Reply to E.J. Moylan et al

by Swain, Sandra M.

Citation: Journal of Clinical Oncology. 32(6):606-7, 2014 Feb 20..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Comment; Letter.Full author list: Swain SM; Tang G; Geyer CE Jr.UI/PMID: 24419136.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1200/JCO.2013.53.8744 (Click here)
40. Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel

by Swain, Sandra M.

Citation: Anti-Cancer Drugs. 24(10):1084-92, 2013 Nov..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article; Research Support, Non-U.S. Gov't.Full author list: Cortes J; Swain SM; Kudaba I; Hauschild M; Patel T; Grincuka E; Masuda N; McNally V; Ross G; Brewster M; Marier JF; Trinh MM; Garg A; Nijem I; Visich J; Lum BL; Baselga J.UI/PMID: 23969513.Digital Object Identifier: http://dx.doi.org/10.1097/CAD.0000000000000016 (Click here)
41. Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31

by Swain, Sandra M.

Citation: Journal of the National Cancer Institute. 105(23):1782-8, 2013 Dec 4..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't.Full author list: Pogue-Geile KL; Kim C; Jeong JH; Tanaka N; Bandos H; Gavin PG; Fumagalli D; Goldstein LC; Sneige N; Burandt E; Taniyama Y; Bohn OL; Lee A; Kim SI; Reilly ML; Remillard MY; Blackmon NL; Kim SR; Horne ZD; Rastogi P; Fehrenbacher L; Romond EH; Swain SM; Mamounas EP; Wickerham DL; Geyer CE Jr; Costantino JP; Wolmark N; Paik S.UI/PMID: 24262440.Digital Object Identifier: http://dx.doi.org/10.1093/jnci/djt321 (Click here)
42. Adjuvant trastuzumab: does time really matter?

by Swain, Sandra M.

Citation: Oncologist. 18(5):490-2, 2013..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article.Full author list: Swain SM.UI/PMID: 23624497.Digital Object Identifier: http://dx.doi.org/10.1634/theoncologist.2013-0094 (Click here)
43. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial

by Swain, Sandra M.

Citation: Lancet Oncology. 14(12):1183-92, 2013 Nov..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't.Full author list: Robidoux A; Tang G; Rastogi P; Geyer CE Jr; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N.UI/PMID: 24095300.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1016/S1470-2045(13)70411-X (Click here)
44. Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial

by Swain, Sandra M.

Citation: Journal of Clinical Oncology. 31(26):3197-204, 2013 Sep 10..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural.Full author list: Swain SM; Tang G; Geyer CE Jr; Rastogi P; Atkins JN; Donnellan PP; Fehrenbacher L; Azar CA; Robidoux A; Polikoff JA; Brufsky AM; Biggs DD; Levine EA; Zapas JL; Provencher L; Northfelt DW; Paik S; Costantino JP; Mamounas EP; Wolmark N.UI/PMID: 23940225.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1200/JCO.2012.48.1275 (Click here)
45. Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study

by Swain, Sandra M.

Citation: Oncologist. 18(3):257-64, 2013..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't.Full author list: Swain SM; Ewer MS; Cortes J; Amadori D; Miles D; Knott A; Clark E; Benyunes MC; Ross G; Baselga J.UI/PMID: 23475636.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1634/theoncologist.2012-0448 (Click here)
46. Pertuzumab : evolving therapeutic strategies in the management of HER2-overexpressing breast cancer. [Review]

by Swain, Sandra M.

Citation: Expert Opinion on Biological Therapy. 13(5):779-90, 2013 May..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article; Research Support, Non-U.S. Gov't; Review.Full author list: O'Sullivan CC; Swain SM.UI/PMID: 23530718.Digital Object Identifier: http://dx.doi.org/10.1517/14712598.2013.783007 (Click here)
47. Avastin withdrawal symptoms

by Lynce, Filipa; Swain, Sandra M.

Citation: Expert Opinion on Pharmacotherapy. 13(3):293-8, 2012 Feb..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Editorial; Research Support, Non-U.S. Gov't.Full author list: Lynce F; Swain SM.UI/PMID: 22263961.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1517/14656566.2012.652088 (Click here)
48. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

by Swain, Sandra M.

Published: 2013Citation: Lancet Oncology. 14(6):461-71, 2013 May..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't.Full author list: Baselga J; Benyunes MC; Campone M; Ciruelos E; Clark E; Cortes J; Ferrero JM; Kim SB; Knott A; Ro J; Ross G; Schneeweiss A; Semiglazov V; Swain SM.UI/PMID: 23602601.Online Access: Click here to access online Digital Object Identifier: (Click here)
49. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials

by Swain, Sandra M.

Citation: Lancet. 379(9814):432-44, 2012 Feb 4..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Comparative Study; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't.Full author list: Early Breast Cancer Trialists' Collaborative Group (EBCTCG); Peto R; Davies C; Godwin J; Gray R; Pan HC; Clarke M; Cutter D; Darby S; McGale P; Taylor C; Wang YC; Bergh J; Di Leo A; Albain K; Swain S; Piccart M; Pritchard K.UI/PMID: 22152853.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1016/S0140-6736(11)61625-5 (Click here)
50. Pazopanib for the treatment of breast cancer. [Review]

by Swain, Sandra M.

Citation: Expert Opinion on Investigational Drugs. 21(2):217-25, 2012 Feb..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article; Research Support, N.I.H., Extramural; Review.Full author list: Amiri-Kordestani L; Tan AR; Swain SM.UI/PMID: 22233389.Digital Object Identifier: http://dx.doi.org/10.1517/13543784.2012.652304 (Click here)
51. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24

by Swain, Sandra M.

Citation: Journal of Clinical Oncology. 30(12):1268-73, 2012 Apr 20..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't.Full author list: Allred DC; Anderson SJ; Paik S; Wickerham DL; Nagtegaal ID; Swain SM; Mamounas EP; Julian TB; Geyer CE Jr; Costantino JP; Land SR; Wolmark N.UI/PMID: 22393101.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1200/JCO.2010.34.0141 (Click here)
52. Bevacizumab added to neoadjuvant chemotherapy for breast cancer

by Swain, Sandra M.

Citation: New England Journal of Medicine. 366(4):310-20, 2012 Jan 26..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S..Full author list: Bear HD; Tang G; Rastogi P; Geyer CE Jr; Robidoux A; Atkins JN; Baez-Diaz L; Brufsky AM; Mehta RS; Fehrenbacher L; Young JA; Senecal FM; Gaur R; Margolese RG; Adams PT; Gross HM; Costantino JP; Swain SM; Mamounas EP; Wolmark N.UI/PMID: 22276821.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1056/NEJMoa1111097 (Click here)
53. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial

by Swain, Sandra M.

Citation: Lancet Oncology. 13(7):734-42, 2012 Jul..Institution: Washington Cancer Institute.Publication: Journal Article.Article type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't.Full author list: Paterson AH; Anderson SJ; Lembersky BC; Fehrenbacher L; Falkson CI; King KM; Weir LM; Brufsky AM; Dakhil S; Lad T; Baez-Diaz L; Gralow JR; Robidoux A; Perez EA; Zheng P; Geyer CE Jr; Swain SM; Costantino JP; Mamounas EP; Wolmark N.UI/PMID: 22704583.Online Access: Click here to access online Digital Object Identifier: http://dx.doi.org/10.1016/S1470-2045(12)70226-7 (Click here)

Powered by Koha